Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab in Stage IIIB/C/D Melanoma Patients with an Integrated Imaging Biomarker
Sponsor: CellSight Technologies, Inc.
Listed as NCT04401995, this PHASE2 trial focuses on Melanoma and remains completed. Sponsored by CellSight Technologies, Inc., it has been updated 18 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
18 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Mar 2024 — Jun 2024 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
▶ Show 13 earlier versions
-
Mar 2023 — Mar 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — May 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
- Checkmate Pharmaceuticals
- Diwakar Davar
For direct contact, visit the study record on ClinicalTrials.gov .